110 related articles for article (PubMed ID: 28956333)
21. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis.
Avila DV; Barker DF; Zhang J; McClain CJ; Barve S; Gobejishvili L
J Pathol; 2016 Sep; 240(1):96-107. PubMed ID: 27287961
[TBL] [Abstract][Full Text] [Related]
22. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Pullamsetti SS; Banat GA; Schmall A; Szibor M; Pomagruk D; Hänze J; Kolosionek E; Wilhelm J; Braun T; Grimminger F; Seeger W; Schermuly RT; Savai R
Oncogene; 2013 Feb; 32(9):1121-34. PubMed ID: 22525277
[TBL] [Abstract][Full Text] [Related]
23. Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases.
Clapcote SJ
Adv Neurobiol; 2017; 17():103-131. PubMed ID: 28956331
[TBL] [Abstract][Full Text] [Related]
24. Targeting phosphodiesterase 4 as a potential therapy for Parkinson's disease: a review.
Nongthombam PD; Haobam R
Mol Biol Rep; 2024 Apr; 51(1):510. PubMed ID: 38622307
[TBL] [Abstract][Full Text] [Related]
25. PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases.
McCahill AC; Huston E; Li X; Houslay MD
Handb Exp Pharmacol; 2008; (186):125-66. PubMed ID: 18491051
[TBL] [Abstract][Full Text] [Related]
26. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.
Rutten K; Van Donkelaar EL; Ferrington L; Blokland A; Bollen E; Steinbusch HW; Kelly PA; Prickaerts JH
Neuropsychopharmacology; 2009 Jul; 34(8):1914-25. PubMed ID: 19262466
[TBL] [Abstract][Full Text] [Related]
27. The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors.
Paes D; Schepers M; Rombaut B; van den Hove D; Vanmierlo T; Prickaerts J
Pharmacol Rev; 2021 Jul; 73(3):1016-1049. PubMed ID: 34233947
[TBL] [Abstract][Full Text] [Related]
28. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.
Andoh T; Kuraishi Y
J Dermatol Sci; 2014 Dec; 76(3):206-13. PubMed ID: 25458869
[TBL] [Abstract][Full Text] [Related]
29. In vivo selective binding of (R)-[11C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues.
Kenk M; Greene M; Thackeray J; deKemp RA; Lortie M; Thorn S; Beanlands RS; DaSilva JN
Nucl Med Biol; 2007 Jan; 34(1):71-7. PubMed ID: 17210463
[TBL] [Abstract][Full Text] [Related]
30. Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice.
Guo J; Lin P; Zhao X; Zhang J; Wei X; Wang Q; Wang C
Neuroscience; 2014 Mar; 263():1-14. PubMed ID: 24434771
[TBL] [Abstract][Full Text] [Related]
31. Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.
Cooney JD; Aguiar RC
Blood; 2016 Dec; 128(25):2886-2890. PubMed ID: 27756749
[TBL] [Abstract][Full Text] [Related]
32. Phosphodiesterase Type 4 Inhibition in CNS Diseases.
Blokland A; Heckman P; Vanmierlo T; Schreiber R; Paes D; Prickaerts J
Trends Pharmacol Sci; 2019 Dec; 40(12):971-985. PubMed ID: 31704172
[TBL] [Abstract][Full Text] [Related]
33. Uncovering the function of Disrupted in Schizophrenia 1 through interactions with the cAMP phosphodiesterase PDE4: Contributions of the Houslay lab to molecular psychiatry.
Brandon NJ
Cell Signal; 2016 Jul; 28(7):749-52. PubMed ID: 26432168
[TBL] [Abstract][Full Text] [Related]
34. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
[TBL] [Abstract][Full Text] [Related]
35. PDE and cognitive processing: beyond the memory domain.
Heckman PR; Blokland A; Ramaekers J; Prickaerts J
Neurobiol Learn Mem; 2015 Mar; 119():108-22. PubMed ID: 25464010
[TBL] [Abstract][Full Text] [Related]
36. Functional characterization of phosphodiesterases 4 in the rat carotid body: effect of oxygen concentrations.
Nunes AR; Batuce JR; Monterio EC
Adv Exp Med Biol; 2009; 648():113-9. PubMed ID: 19536472
[TBL] [Abstract][Full Text] [Related]
37. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
Abbott-Banner KH; Page CP
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
[TBL] [Abstract][Full Text] [Related]
38. UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.
Wang L; Burmeister BT; Johnson KR; Baillie GS; Karginov AV; Skidgel RA; O'Bryan JP; Carnegie GK
Cell Signal; 2015 May; 27(5):908-22. PubMed ID: 25683917
[TBL] [Abstract][Full Text] [Related]
39. Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition.
Abusnina A; Keravis T; Zhou Q; Justiniano H; Lobstein A; Lugnier C
Thromb Haemost; 2015 Feb; 113(2):319-28. PubMed ID: 25230992
[TBL] [Abstract][Full Text] [Related]
40. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
